Takeda Pharmaceutical Company Limited

Kentaro Iwata

Yukihiro Ikeda

Kazuhiro Maeda

Tsuneo Yasuma

Lei Zhu

Yuya Oguro

Mitsuo Yamamoto

Marianne Langston

Naohiro Taya

Misaki Homma

Masato Kitayama

Yasuhiro Sawai

Masahiro Mizuno

Miyuki Hohokabe

John Daniel Bailey

Shruti Gour

Siddhesh Dinanath Patil

Koya Kimoto

Lilly Roy

Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.

Cocrystal

The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I)&#xb7;0.5HO; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.

Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate

The present invention provides a cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and an organic acid capable of forming a cocrystal with the compound.

Cocrystal, production method thereof, and medicament containing cocrystal

Growing community of inventors

Kanagawa, Japan

Kentaro Iwata